Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1800570 | 0.90 | TRPV1 (0.67) | TRPV1RAB9ANPC1NTRK1NTRK2 | |
| SCHEMBL1796368 | 0.88 | TRPV1 (0.62) | TRPV1RAB9ANPC1NTRK1NTRK2 | |
| SCHEMBL12652898 | 0.88 | TRPV1 (0.69) | TRPV1ALDH1A1RAB9ANPC1NTRK1 | |
| SCHEMBL1798966 | 0.86 | TRPV1 (0.66) | TRPV1RAB9ANPC1NTRK1NTRK2 | |
| SCHEMBL12355516 | 0.86 | TRPV1 (0.72) | TRPV1RAB9ANPC1NTRK1SMN1; SMN2 | |
| SCHEMBL12350131 | 0.86 | TRPV1 (0.64) | TRPV1RAB9ANPC1NTRK1SMN1; SMN2 | |
| SCHEMBL1795026 | 0.85 | TRPV1 (0.63) | TRPV1RAB9ANPC1NTRK1SMN1; SMN2 | |
| SCHEMBL2241285 | 0.84 | TRPV1 (0.85) | TRPV1RAB9ANPC1NTRK1NTRK2 | |
| SCHEMBL12350135 | 0.83 | ALDH1A1 (0.43) | TRPV1ALDH1A1RAB9ANPC1CNR2 | |
| SCHEMBL1795997 | 0.83 | TRPV1 (0.62) | TRPV1RAB9ANPC1NTRK1NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | TRPV1 29/4885ALDH1A1 528/4885RAB9A 3985/4885 |
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | TRPV1 29/4885ALDH1A1 528/4885RAB9A 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.